Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) WACC %:11.84% (As of Jul. 06, 2026) — 25% Above Median


CAI:RMDA Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA
84 GF Score
Price E£5.10
GF Value E£4.08
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents WACC %?

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA +1.80% 84 WACC % is 11.84% as of Jul. 06, 2026, which is 25% above its 10-year median of 9.44. GuruFocus rates CAI:RMDA with a GF Score™ of 84/100 and a GF Value™ of E£4.08 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 1,019 Drug Manufacturers companies, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks worse than 77.33% on this metric.

As of today (2026-07-06), Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's weighted average cost of capital is 11.84%%. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's ROIC % is 17.69% (calculated using TTM income statement data). Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents  (CAI:RMDA) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's weighted average cost of capital is 11.84%%. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's ROIC % is 17.69% (calculated using TTM income statement data). Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents WACC % Historical Data

* Premium members only.

The historical data trend for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents WACC % Chart

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
WACC %
Get a 7-Day Free Trial 7.69 9.44 11.23 12.36 12.37

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.19 12.40 12.71 12.37 11.97

CAI:RMDA vs ZTS, UTHR, VTRS: WACC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents WACC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's WACC % distribution charts can be found below:

* The bar in red indicates where Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's WACC % falls into.


CAI:RMDA
84GF Score
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's market capitalization (E) is E£10200.000 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's latest one-year quarterly average Book Value of Debt (D) is E£2127.612 Mil.
a) weight of equity = E / (E + D) = 10200.000 / (10200.000 + 2127.612) = 0.8274
b) weight of debt = D / (E + D) = 2127.612 / (10200.000 + 2127.612) = 0.1726

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.485%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.485% + 1 * 6% = 10.485%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2026, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's interest expense (positive number) was E£530.549 Mil. Its total Book Value of Debt (D) is E£2127.612 Mil.
Cost of Debt = 530.549 / 2127.612 = 24.9364%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 118.515 / 449.037 = 26.39%.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.8274*10.485%+0.1726*24.9364%*(1 - 26.39%)
=11.84%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 11.84% mean?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) has a WACC % of 11.84% as of Jul. 06, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. This is 25% above median its historical median of 9.44. Over the past decade, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' WACC % has ranged from 7.46 to 12.37. According to the industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #788 out of 1019 companies in the Drug Manufacturers industry, placing it in the top 77.3%.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' WACC % too high?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' current WACC % of 11.84% is 25% above median its 10-year median of 9.44. Over the past 10 years, this metric has ranged from a low of 7.46 to a high of 12.37. The Drug Manufacturers industry median WACC % is 8.94. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' value of 11.84% is 32.4% above this industry median. Based on the distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #788 out of 1019 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' WACC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #788 out of 1019 companies for WACC %. This places Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents in the lower half of its industry. The industry median WACC % is 8.94. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' value of 11.84% is 32.4% above this benchmark. Historically, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' own WACC % has ranged from 7.46 to 12.37 over the past decade. While the company's 10-year median is 9.44 vs. the industry median of 8.94, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Drug Manufacturers company?
The median WACC % among Drug Manufacturers companies is 8.94, based on 1,019 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current WACC % of 11.84% is 32.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. For the Drug Manufacturers industry, the median WACC % is 8.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current WACC % is 11.84%, which is 25% above median its own 10-year median of 9.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock overvalued right now?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) is currently considered Modestly Overvalued. The stock's GF Value™ is E£4.08, compared to a current price of E£5.10 — trading 25% above its estimated fair value. The current WACC % is 11.84%, which is 25% above median its 10-year median of 9.44 and 32.4% above the Drug Manufacturers industry median of 8.94. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA), the current WACC % is 11.84% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?

Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued. The current stock price of E£5.10 is trading 25% above its estimated GF Value™ of E£4.08. GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Modestly Overvalued.

Key valuation signals for CAI:RMDA:

  • WACC %: 11.84% (25% above median its 10-year median of 9.44)
  • GF Value™: E£4.08 vs. price of E£5.10 (25% above fair value)
  • GF Score™: 84/100 with 9 warning signs
  • Industry Position: 32.4% above the Drug Manufacturers median (#788 of 1019)

No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Business Description

Address No. 5 Second Industrial Zone, Sixth of October City, Giza, EGY
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
84GF Score

Get the complete analysis for CAI:RMDA

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£5.10
Price
E£4.08
GF Value